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Abstract 
Drug-induced liver injury (DILI) is the greatest cause of post-marketing drug withdrawal; therefore, 
substantial resources are directed towards triaging potentially dangerous new compounds at all 
stages of drug development. One of the major factors preventing effective screening of new 
compounds is the lack of a predictive in vitro model of hepatotoxicity. Primary human hepatocytes 
offer a metabolically-relevant model for which the molecular initiating events of hepatotoxicity 
can be examined; however, these cells vary greatly between donors and dedifferentiate rapidly in 
culture. iPSC-derived hepatocyte-like cells offer a reproducible, physiologically-relevant and 
genotypically-normal model cell; however, current differentiation protocols produce hepatocyte-
like cells with a relatively immature phenotype. During the reprogramming of somatic cells, the 
epigenome undergoes dramatic changes; however, this ‘resetting’ is a gradual process, resulting in 
an altered differentiation propensity, skewed towards the lineage of origin, particularly in early 
passage cultures. We therefore performed a comparison of human hepatocyte- and dermal 
fibroblast-derived iPSCs, assessing the impact of epigenetic memory at all stages of hepatocyte-
like cell differentiation. These results provide the first isogenic assessment of the starting cell type 
in human iPSC-derived hepatocyte-like cells. Despite a trend towards improvement in hepatic 
phenotype in albumin secretion and gene expression, few significant differences in hepatic 
differentiation capacity were found between hepatocyte and fibroblast-derived iPSCs. We 
conclude that the donor and inter-clonal differences have a greater influence on the hepatocyte 
phenotypic maturity than the starting cell type. Therefore, it is not necessary to use human 
hepatocytes for generating iPSC-derived hepatocyte-like cells.  
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Introduction 
Drug induced liver injury (DILI) confers major clinical burden onto healthcare providers
1, 2
 and is the 
most common cause of post-marketing drug withdrawal
3
, yet a method to accurately predict a toxic 
liability or model the mechanisms which cause DILI remains elusive. This is in part due to the lack of 
a translatable in vitro model which reliably triages potentially dangerous compounds during drug 
development or allows for mechanistic analyses. The gold standard for investigating DILI is the 
primary human hepatocyte (PHH) due to their metabolic competence; however, PHH dedifferentiate 
rapidly in culture and vary greatly between donors
4
. Conversely, hepatic cell lines are scalable and 
readily available but only represent a single (abnormal) genotype and lack metabolic relevance
5
. 
Therefore, an expandable, metabolically-relevant, reproducible, population-representative and 
physiologically/genotypically normal source of cells would be an invaluable resource for 
investigating and predicting DILI.  
One such resource which has the potential to address the role of hepatocytes in hepatotoxicity is 
induced pluripotent stem cells (iPSC)-derived hepatocyte-like cells (HLCs). Consequently, the 
generation of HLCs has been an area of intense research since the first differentiation protocols 
were described in 2004 by Lavon et al
6
. In the intervening years, incremental improvements have 
been seen in both efficiency of differentiation and phenotype maturity. Despite these 
improvements, the hepatic phenotype still remains closer to a foetal or neonatal expression profile 
rather than an adult phenotype
7-9
. This has led researchers to look elsewhere for improvements in 
the differentiation of stem cells towards HLCs, including the use of different extracellular 
substrates
10
, 3D culture systems
11
, small molecules
12
 and products of the microbiome
13
.  
One further area of interest has been to investigate the cell of origin. Previous work has shown that 
during the reprogramming process, the hypermethylation of the genes associated with the somatic 
cell phenotype occurs at a relatively late stage of induced pluripotency
14
. Consequently, induced 
pluripotent stem cells (iPSCs) maintain a memory of the cell from which they were derived
15
. This 
phenomenon, termed epigenetic memory, was first described by two separate studies in 2010 
16, 17
 
demonstrating that the starting cell type can influence the differentiation propensity of the iPSC 
towards the lineage of origin.  This was subsequently found to be true of other cell types, such as 
pancreatic β cells, which demonstrated increased PDX1 and insulin gene expression in 
spontaneously differentiated iPSCs-derived from β cells when compared to non-β cell-derived iPSCs 
and ESCs 
18
.  
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Epigenetic memory has also been investigated using hepatocytes (table 1); however, no study has 
provided definitive proof of whether the starting cell type significantly impacts upon the hepatic 
differentiation capacity of iPSCs. Genotype-controlled experiments in mice have shown a transient 
advantage in HLC gene expression of albumin and CK18 in hepatic-derived iPSCs compared to MEF-
derived iPSCs 
19
. However, this advantage was greater when iPSCs were derived from hepatoblasts 
than mature hepatocytes and dissipated with time in culture. Liu et al., published the first human 
comparison in 2011
20
, demonstrating no significant advantage in hepatic phenotype when PHH-
derived iPSCs were compared to iPSCs derived from other cell types derived from different donors, 
as measured by albumin secretion, CYP3A activity assays; however, a similar but distinct global 
epigenetic profile was reported 
20
.  
More recently, Takayama et al. corroborated the report from Lee et al.,
19
 in human cells, 
demonstrating a small but significant advantage when hepatocytes were compared to other cell 
types; however, the cells were sourced from different donors and the advantage was again found to 
dissipate with time in culture
21
. The importance of donor-dependent genetic differences was further 
highlighted by Kajiwara et al., who showed that donor differences were the largest determinant of 
hepatocyte-like cell quality, rather than the cell of origin, although this study did not use PHH-
derived iPSCs
22
.  
Therefore, the investigation of epigenetic memory in hepatocyte-like cells can only be truly assessed 
using a comparison of human genotype-controlled iPSCs derived from hepatocytes and non-
hepatocytes isolated from the same donor. Herein, we describe the comparison of isogenic PHH- 
and dermal fibroblast derived iPSCs and the hepatic differentiation potential of these cells.    
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Methods 
Primary human hepatocyte and dermal fibroblast isolation and culture 
Liver and skin resections were received as surgical waste (Aintree hospital, Liverpool, United 
Kingdom) with full patient consent and ethical approval from the relevant institutional review 
boards (National Research Ethics Service REC ref: 11/NW/0327). Primary human hepatocytes were 
isolated using a modified version of the previously described 2-step collagenase method as 
previously described
23
. 
Human dermal fibroblasts (HDFs) were isolated using a previously published protocol
24
. Skin biopsies 
were cut using scalpel and forceps into approximately 1cm
2 
pieces and placed into a 6 well plate (3 
pieces/well). Two drops of Dulbecco's modiﬁed Eagle's medium (DMEM; Sigma Aldrich, St. Louis, 
MO) supplemented with 10% (v/v) foetal bovine serum (FBS; Life technologies, Carlsbad, CA), 2mM 
L-glutamine  (Sigma-Aldrich) and 1% (v/v) penicillin/streptomycin (Sigma-Aldrich; HDF media) were 
placed on top of each segment and left to attach overnight. Drops of HDF media were replaced daily 
to keep the pieces submerged. After 7 days, 1ml of media was added/well and changed every 48 
hours. After 2 weeks HDF outgrowths were observable. Once confluent, HDFs were detached with 
0.05% trypsin (Sigma Aldrich) and expanded for reprogramming and cryopreservation.  
Sendai virus reprogramming of PHH and HDFs 
PHH were plated on embryonic stem cell (ESC)-qualified Matrigel (Corning, Corning, NY) at a density 
of 1x10
5
 – 5x10
5
 cells/well in a 6 well plate. Cells were cultured in Williams E medium supplemented 
with 2.5% (v/v) FBS (Life technologies), 50ng/ml hepatocyte growth factor (HGF; Promokine, 
Heidelberg, Germany), 50ng/ml epidermal growth factor (EGF, Life technologies), 15mM HEPES 
buffer (Sigma-Aldrich), 100nM dexamethasone (Sigma-Aldrich), 0.2% (v/v) insulin-transferrin-
selenium (Life technologies) and 0.5% (v/v) penicillin/streptomycin (PHH reprogramming media). 
Following 3 days of culture, Sendai viruses containing Oct4, Sox2, Klf4 and c-Myc transcription 
factors (Life technologies) were added at multiplicities of infection (MOI) 3-10. After 24 hours, media 
was replaced with non-virus containing PHH reprogramming media and culture continued for a 
further 2 days. Subsequently, cells were then cultured in Essential 6 media (Life technologies) 
containing basic fibroblast growth factor (bFGF; 100ng/ml; Life technologies) and 0.5% (v/v) 
penicillin/streptomycin for 25-30 days, replacing the media every 24 hours.  
HDFs were plated in a 6 well plate at 5x10
6
 cells/well or 3x10
5
 cells/ well, respectively. After 48 hours 
of culture, cells were transduced with Sendai viruses containing Oct4, Sox2, Klf4 and c-Myc at MOI 3 
or 5. After 24 hours, media was replaced and changed every 48 hours for 7 days. On day 7 of 
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reprogramming, cells were trypsinised (0.05% trypsin) and re-plated onto 10cm
2
 dishes coated with 
mouse embryonic fibroblasts (MEFs; Globalstem, Rockville, MD) or 6 well plates coated with 
Matrigel. Cells were plated in HDF media which was replaced with either DMEM/F12 media 
supplemented with 20% (v/v) KnockOut serum replacement media, 1x non-essential amino acids, 
50µM 2-mercaptoethanol (Life technologies) and 0.5% (v/v) penicillin/streptomycin on MEF cultures 
or Essential 6 media supplemented 100ng/ml basic-FGF (Life technologies) for Matrigel cultures. 
Media was changed daily and colonies formed from day 21 onwards. 
iPSCs were maintained on either MEF-coated plates in DMEM/F12 media supplemented with 20% 
(v/v) KnockOut serum replacement media, 1x non-essential amino acids, 50µM 2-mercaptoethanol 
and 0.5% (v/v) penicillin/streptomycin or on Matrigel in Essential 8 medium. All early passage 
comparison assays were performed using <p10 (donors 1 and 2) or <p15 (donor 3) iPSCs. 
Characterisation was performed using iPSCs >p15 and late passage analysis was conducted using 
iPSCs >p30.   
Differentiation to hepatocyte-like cells 
Cells were transferred to Matrigel culture 1:1 from MEF culture and cultured in Essential 8 medium. 
Upon confluence, cells were washed once with Dulbecco’s phosphate buffered saline (DPBS) and 
disassociated with Accutase at 37
°
C for ~5 minutes. Cells were then centrifuged at 200 x g for 5 
minutes and re-suspended in RPMI media supplemented with 1x B27 and 10µM ROCK inhibitor 
(Merck Millipore, Billerica, MA). Cells were then counted and plated at 1.5x10
5
 cells/cm
2
 on Matrigel 
coated 24 well plates in RPMI media (Life technologies) supplemented with 1x B27 (Life 
technologies), 0.5% (v/v) penicillin/streptomycin, 10µM ROCK inhibitor (Merck Millipore), 100ng/ml 
Activin A and 50ng/ml Wnt3a (R&D Systems, Minneapolis, MN). Following overnight plating, cell 
media was replaced daily with RPMI media containing 1x B27, 0.5% (v/v) penicillin/streptomycin, 
100ng/ml Activin A and 50ng/ml Wnt3a. After 3 days, Wnt3a was omitted from the media for a 
further 2 days. At day 5, media was replaced with KnockOut DMEM media containing 20% (v/v) 
KnockOut serum, 1mM L-glutamine, 0.5% (v/v) penicillin/streptomycin, 1x non-essential amino 
acids, 100µM 2-mercaptoethanol and 1% (v/v) DMSO. Media was changed every 48 hours for 7 days. 
At day 12, media was replaced with HepatoZyme culture media (Life Technologies) supplemented 
with 2mM L-glutamine, 0.5% (v/v) penicillin/streptomycin, 20ng/ml HGF, 20ng/ml OSM (Promokine) 
and 100nM dexamethasone. At day 22, cells were lysed for HLC comparisons. Samples were also 
taken at definitive endoderm (day 5) and hepatic endoderm (day 12) stages.  
Spontaneous differentiation assays 
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Cells were disassociated using gentle cell disassociation reagent (Stem Cell Technologies; Vancouver, 
British Columbia, Canada) and scraped in to DMEM/F12 media supplemented with 20% (v/v) 
KnockOut serum, 1x non-essential amino acids, 100µM 2-mercaptoethanol, 0.5% (v/v) 
penicillin/streptomycin and 10µM ROCK inhibitor. MEFs were removed by gravitational separation 
and cells plated in 12-well non-tissue culture treated plates (Corning) in triplicate (1:1 ratio). Media 
was changed every 48 hours without ROCK inhibitor. For gene expression comparisons, cells were 
cultured for 16 days before lysing in QIAzol (QIAgen). For characterisation experiments, cells were 
cultured for 7 days, before transfer to attachment factor-coated 48 well tissue-culture treated plates 
for re-attachment. Cells were cultured for a further 7 days, before fixing with 4% (v/v) PFA for 
immunofluorescence assessment.  
Pyrosequencing  
DNA was extracted using the QIAamp DNA mini kit according to the manufacturer’s instructions 
(QIAgen). 250ng DNA/sample was then bisulphite converted using the EZ DNA Methylation-Gold kit 
(Zymo, Irvine, CA) according to the manufacturer’s protocol. Genes bearing CpG islands within their 
promoter region were ascertained using the NCBI gene information and the online tool CpG island 
searcher (http://cpgislands.usc.edu/). PCR and pyrosequencing primers (sequencing, biotinylated 
and non-biotinylated, table S2) were designed using the Pyromark Assay Design 2.0 software 
(QIAgen, Manchester, UK) and purchased from Eurofins (Eurofins, Luxembourg). PCR products were 
generated from the bisulphite-converted samples for all primer sets using optimised conditions. 
Single-strand pyrosequencing templates were generated from PCR product following binding to 
streptavidin beads and subsequent washes with 70% ethanol, 0.2M NaOH and 10mM Tris-Acetate 
pH 7.5. Pyrosequencing was undertaken on a PyroMark Q96 ID instrument (QIAgen). 
Immunofluorescence 
Cells were fixed with 4% (w/v) paraformaldehyde (Sigma Aldrich) for 15 minutes and subsequently 
washed three times with DPBS buffered with MgCl2 and CaCl2
 
(DPBS+; Life technologies). Fixed cells 
were blocked with DPBS+ supplemented with 10% (v/v) donkey serum (Sigma Aldrich) and 0.01% 
(v/v) Triton X-100 (Sigma Aldrich) for 30 minutes. Primary antibodies were diluted (table 2.2) in 
DPBS+ containing 1% (v/v) donkey serum 0.01% (v/v) Triton X-100 and incubated overnight at 4
°
C. 
Cells were washed three times with DPBS+ and alexafluor secondary antibody diluted 1:750 in 
DPBS+ supplemented with 1% (v/v) donkey serum with 0.01% (v/v) triton X-100 added and 
incubated at room temperature for 2 hours. Cells were washed three times and Hoechst stain 
(1mg/ml; Sigma Aldrich) added at a 1:7500 dilution in DPBS+ for 10 minutes. Cells washed three 
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times and imaged using the Axio Observer Z1 fluorescence microscope with the AxioCam MR digital 
camera. Images processed using Zen lite software (Carl Zeiss).    
For albumin staining, 10x blocking buffer (Abcam, Cambridge, United Kingdom) was used to replace 
donkey serum. Staining with Tra-1-60 and SSEA-4 conjugated antibodies was performed without 
triton X-100 and with a single 90 minute incubation at room temperature following blocking with 
10% (v/v) donkey serum in DPBS+.  
qRT-PCR analysis of gene expression 
Primers for use in quantitative reverse transcription polymerase chain reaction (qRT-PCR) gene 
expression studies were designed using the NCBI Primer BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primer quality was assessed using OligoCalc and 
purchased from Eurofins (Table S3). Samples were collected in QIAzol (QIAgen), and extracted using 
the miRNeasy extraction kit according to the manufacturer’s protocol (QIAgen) Extracted RNA 
content was measured using the NanoDrop spectrophotometer (Thermo Fisher Scientific). RNA was 
reverse transcribed to complementary DNA (cDNA) using the ImProm-II reverse transcription kit 
(Promega).  
Due to low RNA yield following extraction, whole transcriptome amplification was performed on 
selected samples using the QuantiTect Whole Transcriptome Kit (Qiagen), following the 
manufacturer’s protocol. Briefly, 100ng of starting RNA from each sample was mixed with reverse 
transcriptase kit component and incubated at 37
°
C for 30 minutes and 95
°
C for 5 minutes. Ligation 
mix was then added to each samples and incubated for 2 hours at 22
°
C. Finally, the amplification mix 
was added and incubated for 8 hours at 30
°
C and 5 minutes at 95
°
C. Temperature controlled steps 
were carried out using the GeneAmp PCR system 9700 thermal cycler system (Applied Biosystem, 
Waltham, MA)  and amplification confirmed using the NanoDrop spectrophotometer. 
Gene expression analysis was performed using the SYBRGreen JumpStart Taq ReadyMix (Sigma 
Aldrich). Briefly, 10-100µg of cDNA was amplified by qRT-PCR as follows: 95
°
C for 10 minutes, then 
40 cycles for 95
°
C 15 seconds and 60
°
C for 60 seconds using the ViiA7 qRT-PCR machine (Applied 
Biosystems). Results were calculated using the CT values generated, normalised against GAPDH or 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and succinate dehydrogenase (SDHA)
25
 and 
calculated relative to a calibrator sample (e.g. PHH) using 2
-∆∆CT
 method 
26
. Sendai virus expression 
analysis of iPSCs was conducted using the TaqMan iPSC Sendai Detection Kit (Life Technologies) 
according the manufacturer’s instructions. Results were normalised using GAPDH and calculated 
relative to the reprogramming plate using 2
-∆∆CT
 method.  
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Metabolism studies 
Cells were incubated for 15 minutes at 37°C (5% CO2) in standard culture media with a final 
substrate cocktail concentration of 1mM testosterone (CYP3A4) and 0.25mM dextromethorphan 
(CYP2D6) (Sigma Aldrich) in MeOH or H2O, respectively (Thermo Fisher Scientific). 0.5µM Phenacetin 
(Sigma Aldrich) in 100% MeOH was then added to the incubation media (1:1 v/v) as a stop solution 
and an internal standard for LC-MS-MS analysis. The media containing the respective metabolites, 
6β-OH-testosterone and dextrorphan, was then filtered using 96-well filter plates (Merck Millipore) 
and analysed by LC-MS-MS. Results were normalised by protein content of the well following 
quantification by Bradford assay. 
Albumin ELISA 
The albumin concentration was measured by ELISA following the manufacturer’s protocol (Bethyl 
Laboratories, Montgomery, TX) protocol. Briefly, 96-well high-affinity binding plates (Thermo Fisher 
Scientific) were coated with coating antibody in coating buffer for 1 hour and subsequently blocked 
with 1% (w/v) bovine serum albumin (BSA; Sigma Aldrich) for 30 minutes. Cell supernatants were 
added to wells at appropriate dilutions and incubated at room temperature for 1 hour. Horseradish 
peroxidase-conjugated detection antibody was then added to each well at a 1:50,000 concentration. 
Following a 1 hour incubation, 3,3′,5,5′-Tetramethylbenzidine substrate solution was added, 
incubated for 20 minutes and the reaction stopped with 0.18M sulphuric acid (Thermo Fisher 
Scientific). Plates were read at 450nm using a MRX
e
 Revelation plate reader (Dynex Technologies, 
Chantilly, VA). 
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Results 
Generation of iPSCs derived from PHH and HDFs of multiple donors. 
To assess the differences between hepatocyte-like cells differentiated from PHH- and HDF-derived 
iPSCs, a reprogramming technique capable of inducing pluripotency in both cell types was required. 
Reprogramming of PHH has been reported as relatively inefficient compared to more traditionally 
used cell types, such as HDFs
27
. Therefore, a technique capable of reprogramming PHH was first 
optimised. 
PHH are known not to respond well to trypsinisation and re-plating, therefore it was hypothesised 
that developing a protocol which did not require re-plating would be the most successful route. 
Furthermore, given that the cell cycle is a vital component of reprogramming
28
, the media 
composition described by Liu et al.,
29
 which contains high levels of known mitogenic factors HGF and 
EGF, was used (Figure S1a). 
Using these conditions, PHH were transduced with the OSKM-containing Sendai viruses at MOI 5 and 
10 and examined during the reprogramming period for colony formation (Figure S2a). At day 20, the 
first colonies were noted with similar, but incomplete iPSC-like morphology. These colonies 
appeared to be heterogeneous and underwent growth arrest during the culture period (Figure S2a). 
At day 24, one colony was noted which exhibited the hallmark features of an iPSC colony (Figure 
S2b). After tracking the colony over several days, the colony remained homogenous and continued 
to expand. This colony was manually picked for expansion and fully characterised.  
Using this protocol, iPSCs were successfully generated from hepatocyte cultures from three separate 
donors (Figure 1 and Table S4). Subsequent to successful PHH-reprograming, the dermal fibroblasts 
of the corresponding donors were also reprogrammed using a well-established dermal fibroblast 
protocol (Figure S1b). Pluripotency was assessed using a panel of embryonic stem cell-enriched 
markers: Oct4, Sox2, Nanog, Tra-1-60 and SSEA-4 (Figure S3). All lines examined demonstrated 
expression of each of the markers, indicating that they had established a pluripotent expression 
profile.  
The functional differentiation capacity of these lines was also assessed using embryoid body (EB) 
assays. This assay encourages cellular differentiation and, if truly pluripotent, should result in 
differentiation towards cell types from all three germ layers: ectoderm, mesoderm and endoderm. 
The presence of each of these germ layers within the differentiated cell population was investigated 
by immunofluorescence, using the markers TUJ1 (Neuron-specific class III beta-tubulin; ectoderm), 
α-SMA (alpha smooth muscle actin; mesoderm) and AFP (Alpha-Fetoprotein; endoderm) (Figure S4). 
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All of the iPSC lines generated stained successfully for these markers, indicating that all selected lines 
were functionally pluripotent.  
Donor-dependent differences in PHH- and HDF-derived iPSCs gene expression profile. 
To fully compare the iPSCs generated from PHH and HDFs, comparisons were required at all stages 
of culture and differentiation. Therefore, the expression of important pluripotency-associated genes 
at the iPSC-stage was compared. Across these markers, Oct4 and Nanog showed similar levels of 
expression between both cell types of origin. Sox2 expression was significantly greater in the PHH-
derived lines for donor 3; however, this was not true of donors 1 and 2 (Figure 2a). Furthermore, 
analysis of Wnt3, which has been proposed as an iPSC marker of definitive endoderm potential (i.e. 
high Wnt3 expression correlates with high purity D.E formation)
30
, again showed no significant 
differences between PHH and HDF-derived iPSCs; however, a donor-dependent difference was 
observed (Figure S5).  
HNF4α promoter analysis in PHH- and HDF-derived iPSCs demonstrates a small but consistent cell-
type specific difference in methylation which decreases with time in culture.  
As the inherent memory of iPSCs is reported to be a consequence of incomplete epigenetic 
reprogramming, the potential differences seen between PHH- and HDF-derived lines at the iPSC 
stage were investigated. In this context, we assessed the methylation status of key hepatic genes: 
HNF4α and FOXA2, since their epigenetic status would likely influence the differentiation status of 
the HLCs. During the process of reprogramming, the methylation of HNF4α and FOXA2 promoter 
regions in both PHH and HDFs was significantly increased to similar levels between PHH and HDF-
derived clones (Figure 2b). We assessed global methylation utilising an assay for LINE1 (Long 
interspersed nuclear elements retrotransposable element 1) which is repeated throughout the 
genome and therefore often used as a surrogate marker of whole genome methylation status
31
. Our 
results indicated very similar global methylation indexes between PHH- and HDF-derived iPSCs 
(65.35% and 65.43%, respectively; Figure 2b).  
Notwithstanding the global methylation similarity, across the five CpG sites examined within the 
HNF4α promoter region, each site was consistently ~1% less methylated in the PHH-derived lines 
when compared to the HDF-derived lines (Figure 2c). Across all lines and CpG sites investigated, 
1.22% less methylation was observed in PHH-derived samples; however, this trend was found to 
decrease with time in culture, with a difference of 0.42% methylation between late passage PHH-
derived and HDF-derived iPSCs (Figure 2d). No conserved methylation differences were found 
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between PHH and HDF-derived iPSCs in the FOXA2 promoter; however, FOXA2 methylation was 
found to increase (1.22%) between early and late passage iPSCs.  
Spontaneous differentiation of PHH- and HDF-derived iPSCs reveals the greatest discriminator 
between the iPSCs is the donor, rather than the starting cell type.  
To investigate if the cell-type of origin influences the inherent differentiation propensity of iPSCs, the 
hepatic/endoderm-enriched gene expression of embryoid bodies (EBs) was compared. Using a 
previously published method for comparing iPSCs of different origins
18
, EBs were generated and 
cultured in suspension for 16 days. The expression of known endoderm and hepatic markers was 
then compared. 
The results presented in figure 3 suggested a very slight trend towards the enhancement of hepatic-
associated gene expression in PHH-derived EBs in five of the genes tested, i.e. Albumin, AFP, SOX17, 
FOXA2 and CXCR4. However, GATA4 and HNF4α showed a trend towards higher expression in the 
HDF-derived clones. Despite these trends, only Sox17 showed significantly greater expression in 
PHH-derived iPSCs, although this difference was only observed in one of the three donors. Taken 
together there was very little difference in the spontaneous differentiation propensity of PHH and 
HDF-derived iPSCs across the investigated hepatic and endodermal-associated genes. Indeed, the 
greatest determinant of gene expression appeared to be the donor, rather than the starting cell 
type.  
Donor- and clonal-dependent variation are a greater influence on the gene expression of hepatocyte-
like cells than the starting cell type. 
The differentiation of iPSCs towards hepatocyte-like cells was achieved using a protocol adapted 
from previous publications
22, 32
(Figure S6a) and successful differentiation was confirmed by 
immunofluorescence at each stage: definitive endoderm (D.E; Sox17), hepatic endoderm (H.E; 
HNF4α) and HLCs (Albumin) (Figure S6b).   
To fully evaluate the differentiation procedure and to assess any inherent advantage as a result of 
the different starting cell types, we compared the gene expression at each stage of differentiation. 
Figure S7a demonstrates a comparison of several key markers of definitive endoderm. The results 
followed a similar pattern to previous analysis, demonstrating no significant differences between 
starting cell types when the gene expression of FOXA2, SOX17 and GATA4 was compared. 
Interestingly, both GATA4 and FOXA2, showed a larger dependence on the donor of origin than 
starting cell type.  
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Similar analysis was also undertaken for the hepatic endoderm stage of differentiation, using AFP 
and HNF4α as stage-specific markers. Despite a trend towards enhanced levels of both markers in 
the PHH-derived iPSCs, due to inter-clonal variation, only HNF4α in donor 2 demonstrated 
significantly enhanced gene expression in PHH-derived hepatic endoderm (Figure S7b).  
Final stage HLCs were then compared using a panel of mature and immature hepatic markers 
alongside functional assays with the individual donor’s PHH used as the gold standard comparator 
(Figure 4, Figure 5 and S8).  
Gene expression analysis of these markers demonstrated no significant differences between the 
lines generated from different cell types in any of the donors. Despite this, some genes did show a 
trend towards improved gene expression in the PHH-derived clones; for example, in all three donors, 
greater expression of HNF4α and CYP2D6 is found in PHH-derived HLCs when compared to the 
corresponding donor’s HDF-derived HLCs. Conversely, the other markers lack conformity, with the 
greater expression of the marker gene differing between PHH and HDF-derived HLCs across the 
assessed donors (Figure 4c).  
Functional comparisons show no significant difference between PHH- and HDF-derived hepatocyte-
like cells.    
To assess the functional capacity of the HLCs, albumin secretion was compared at day 22 of 
differentiation. The data demonstrated a non-significant trend pointing towards PHH-derived clones 
having slightly higher, but non-significantly different, albumin secretion in two of the three donors 
(Figure 5a). When examined together, the difference between PHH- and HDF-derived HLC albumin 
secretion was not statistically significant (Figure 5b). 
CYP3A and CYP2D6 activity was also assessed using probe substrates testosterone and 
dextromethorphan, respectively (Figure 5c and d). Again, no significant differences were found 
between the HLCs derived from the different starting cell types.  
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Discussion 
In this study, we have investigated the hepatocyte differentiation potential of PHH- and HDF-derived 
iPSCs derived from the same donor in a multi-faceted panel of assays, to give a thorough comparison 
of the hepatic phenotype.  
Our main hypothesis, that the starting cell type influences the differentiation capacity of the cell, 
was driven by the reported epigenetic memory which remains from the somatic cell following 
reprogramming
16, 17
. Our results suggested a small but statistically non-significant epigenetic 
memory may be found in the developmentally important liver-enriched transcription factor HNF4α 
promoter region in reprogrammed cells derived from human hepatocytes
34, 35
. This is in contrast to 
25% difference in the methylation of the PDX1 gene promoter region reported between beta-
pancreatic cell-derived iPSC and non-beta-pancreatic cell-derived iPSCs
18
. Throughout the analysis, a 
general trend towards a slight, non-significant advantage, to starting with primary human 
hepatocytes, when compared to dermal fibroblasts, was also noted. This was most evident with 
HNF4α expression at the hepatic endoderm stage of differentiation. Therefore, the slightly enhanced 
phenotype in PHH-derived iPSCs at the HLC stage may be driven by the small differences in the 
methylation patterns of HNF4α reported in this study and other hepatic-associated genes. 
Moreover, the lack of a clear enhancement in cell differentiation, as described in pancreatic beta 
cell-derived iPSCs
18
, may be a consequence of the relatively small differences in the epigenetic 
profile of PHH- and HDF-derived iPSCs. Our findings that the noted differences in HNF4α methylation 
decrease with time in culture are in keeping with previous literature, which has demonstrated that 
the distinct epigenetic patterns and enhanced phenotype in a given cell type-derived iPSC are lost 
following repeat passaging 
16, 17, 19, 21
.  
Throughout this study, few significant differences were found between the PHH- and HDF-derived-
iPSCs. Recent work has suggested that the major determinant in hepatocyte-like cell differentiation 
phenotype is the donor
22
. This was found to be true for the gene expression analysis of the iPSC, 
definitive endoderm and embryoid body samples. The gene expression profile of HLCs has been 
reported to be influenced by the genotype of the corresponding donor PHH
21, 36
. Therefore, to 
reduce genotype-derived donor variation and allow for a more representative comparison of the 
starting cell type, HLC samples were compared to the corresponding donor’s PHH. Despite this 
analytical approach, no significant differences were found between PHH- and HDF-derived HLCs.  
Whilst the donor appears to be a major determinant of phenotype, other non-defined factors, not 
related to starting cell type or donor, also appear to influence the hepatic differentiation capacity of 
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iPSCs. This inter-clonal variation contributed to the lack of significant findings between starting cell 
types. For example, albumin secretion was found to be generally higher in PHH-derived clones; 
however, when all lines were compared, no significant differences were seen between PHH- and 
HDF-derived lines. This was in part due to the donor 1 HDF-derived line, Liv4FA, which displayed 
much greater albumin secretion and gene expression than all other lines. If Liv4FA is not included in 
the analysis, there is significantly greater HLC albumin secretion in lines derived from PHH. Thus, our 
results suggest that both donor- and clone-dependent variation has greater influence on HLC 
phenotype than the starting cell type. Further work is therefore required to define the differences 
between iPSC clones which infer the capacity for hepatic differentiation.  
Previous work has described the reprogramming of human hepatocytes as being relatively inefficient 
compared to HDFs and that it was only achievable with cells derived from relatively young donors 
27
. 
In contrast, we were able to generate clones from donors which were comparatively old, i.e. 63 and 
66 years old. Interestingly, despite using only four clones for the analysis, we were able to generate 
10 clones from donor 3 (27 years old). These data point towards an enhancement of hepatocyte 
reprogramming efficiency in younger donors. The effect of age has been discussed in depth in other 
starting cell types; with multiple studies in mice showing a decline in reprogramming efficiency with 
age
37
. However, the effect of age on reprogramming efficiency in human cells is more difficult to 
assess due to the unknown influence of the donor’s genetic background. As a consequence the 
effect of age is under debate; Sommers et al., reported no significant correlation between age and 
efficiency
38
, whereas, Trockovic et al., did find a correlation, in a P21-dependent manner
39
. 
The isolation of PHH is relatively well-established; however, the lack of a bona fide cell surface 
marker and the sensitivity of the cells during the isolation process mean that, to the best of our 
knowledge, a 100% homogenous population of hepatocytes is not currently achievable. Therefore, 
there remains a possibility that not all of the iPSC clones derived from the PHH-enriched population 
were derived from hepatocytes. However, if PHH-derived clones were to be used in future 
experiments, the inability to guarantee a homogenous starting population of hepatocytes will likely 
remain; therefore, this work is also representative of the practical limitations associated with PHH as 
a starting cell source.  
It must also be acknowledged that the slight enhancements seen in PHH-derived clones may well be 
limited by the restricted differentiation maturity which is currently achievable in simple 2D HLC 
culture systems, as used in this study. In line with this, our PHH-derived iPSCs do appear to show a 
significant trend (Figure S6b) towards enhancement of phenotype at the hepatic endoderm stage 
which is carried through to our HLC analysis. Previous work in mice has shown that the greatest 
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advantage in HLC differentiation was achieved by reprogramming hepatoblasts, rather than adult 
hepatocytes
19
. This may be a consequence of the relatively immature phenotype of HLCs. Therefore, 
future investigations into the starting cell type would require the development of protocols which 
produce a more mature phenotype; however, this in itself remains a major bottleneck in the field of 
HLCs 
7
. Moreover, through the inclusion of spontaneous differentiation assays and methylation 
analysis alongside our HLC comparisons, we have demonstrated that the starting cell type is unlikely 
to be of significant influence, even when protocols which allow for enhanced differentiation are 
developed.   
Taken together, the lack of any major advantage to PHH-derived iPSCs is of significance to the field 
of iPSC-derived HLCs, suggesting that any trend towards enhanced expression in PHH-derived clones 
is not greater than the inter-clone and donor variation derived from other non-defined influencing 
factors. Furthermore, the access and phenotypic range of available PHH samples is very restricted in 
comparison to the easily accessible skin or blood samples used in the majority of current studies
24, 40
. 
Therefore, the similarity between the cell types for all tested parameters is reassuring for current 
and future studies, particularly those which require specific genotypic backgrounds, i.e. for disease 
studies, or a large phenotypic range for population-representative studies.   
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Figure legends 
Figure 1: Isolation and reprogramming of somatic cells. The morphology of PHH and HDFs from each 
donor prior to reprogramming and selected examples of the iPSCs which were generated from each 
of these starting cell types/donors. PHH: Magnification: x100, scale bar: 100µm; iPSCs and HDFs: 
magnification x40, scale bar: 100µm.  
Figure 2: Comparison of iPSC gene expression by qRT-PCR and methylation status by 
pyrosequencing. a) Nanog, Sox2 and Oct4 gene expression determined by qRT-PCR and presented as 
2
-ΔΔ
CT relative to hESC comparator and normalised with GAPDH. (*) denotes p>0.05 unpaired T test. 
b) The changes in methylation status of HNF4α, FOXA2 and Line1 in PHH (48hrs culture) and HDFs 
pre- and post-reprogramming. (*) denotes p>0.05 one-way ANOVA. c) the difference in HNF4α 
methylation status of the PHH- and HDF-derived iPSCs across the 5 CpG sites located in the analysed 
sequence. d) The methylation status of HNF4α and FOXA2 which occur following repeat passaging of 
the cells during standard culture procedures.  
Figure 3: Comparison of endoderm and hepatic associated gene expression in PHH- and HDF derived 
embryoid bodies using qRT-PCR. All genes shown as 2
-ΔΔ
CT relative to a hESC-derived EB comparator 
and normalised to GAPDH and Succinate dehydrogenase. Error bars represent standard deviation 
between the means of each PHH-/HDF-derived iPSC line which were derived from three individual 
differentiation cultures. Each sample tested by qRT-PCR was loaded in duplicate. (*) denotes p>0.05 
unpaired T test. 
Figure 4: Comparison of hepatocyte-like cell gene expression measured by qRT-PCR. Gene 
expression of key hepatic genes obtained by q-PCR analysis. Results normalized using GAPDH and 
Succinate dehydrogenase and displayed as 2
-ΔΔ
CT relative to PHH of the corresponding donor. ★N.B. 
Donor 1 shown relative to isogenic plated PHH; donor 2 and 3 shown relative to non-plated isogenic 
PHH. Error bars represent standard deviation between the means of each PHH-/HDF-derived iPSC 
line which were derived from three individual differentiation cultures. Each sample tested by qRT-
PCR was loaded in duplicate. (*) denotes p>0.05 unpaired T test. 
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Figure 5: Functional comparison of hepatocyte-like cells. a) albumin secretion in PHH and PHH- and 
HDF-derived HLCs at the final stage of differentiation measured by ELISA and normalised using total 
protein content of corresponding well. (*) denotes p>0.001 one-way ANOVA. Error bars: SD. b) 
Albumin secretion comparison of PHH and HDF-derived HLCs from all three donors *p>0.05 unpaired 
T test. c) and d) CYP activity as detected using LC-MS-MS method analysing the turnover of probe 
substrates and quantification of metabolites for c) 6β-OH-testosterone (CYP3A) and d) Dextrorphan 
(CYP2D6). * denotes p>0.05 one-way ANOVA. Error bars: SD.  
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Figure 1: Isolation and reprogramming of somatic cells. The morphology of PHH and HDFs from each donor 
prior to reprogramming and selected examples of the iPSCs which were generated from each of these 
starting cell types/donors. PHH: Magnification: x100, scale bar: 100µm; iPSCs and HDFs: magnification x40, 
scale bar: 100µm.  
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Figure 2: Comparison of iPSC gene expression by qRT-PCR and methylation status by pyrosequencing. a) 
Nanog, Sox2 and Oct4 gene expression determined by qRT-PCR and presented as 2-∆∆CT relative to hESC 
comparator and normalised with GAPDH. (*) denotes p>0.05 unpaired T test. b) The changes in methylation 
status of HNF4α, FOXA2 and Line1 in PHH (48hrs culture) and HDFs pre- and post-reprogramming. (*) 
denotes p>0.05 one-way ANOVA. c) the difference in HNF4α methylation status of the PHH- and HDF-
derived iPSCs across the 5 CpG sites located in the analysed sequence. d) The methylation status of HNF4α 
and FOXA2 which occur following repeat passaging of the cells during standard culture procedures.  
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Figure 3: Comparison of endoderm and hepatic associated gene expression in PHH- and HDF derived 
embryoid bodies using qRT-PCR. All genes shown as 2-∆∆CT relative to a hESC-derived EB comparator and 
normalised to GAPDH and Succinate dehydrogenase. Error bars represent standard deviation between the 
means of each PHH-/HDF-derived iPSC line which were derived from three individual differentiation cultures. 
Each sample tested by qRT-PCR was loaded in duplicate. (*) denotes p>0.05 unpaired T test.  
 
653x460mm (96 x 96 DPI)  
 
 
Page 23 of 39
ScholarOne Support: (434) 964-4100
Stem Cells Translational Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Comparison of hepatocyte-like cell gene expression measured by qRT-PCR. Gene expression of key hepatic 
genes obtained by q-PCR analysis. Results normalized using GAPDH and Succinate dehydrogenase and 
displayed as 2-∆∆CT relative to PHH of the corresponding donor. ★N.B. Donor 1 shown relative to isogenic 
plated PHH; donor 2 and 3 shown relative to non-plated isogenic PHH. Error bars represent standard 
deviation between the means of each PHH-/HDF-derived iPSC line which were derived from three individual 
differentiation cultures. Each sample tested by qRT-PCR was loaded in duplicate. (*) denotes p>0.05 
unpaired T test.  
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Figure 5: Functional comparison of hepatocyte-like cells. a) albumin secretion in PHH and PHH- and HDF-
derived HLCs at the final stage of differentiation measured by ELISA and normalised using total protein 
content of corresponding well. * denotes p>0.001 one-way ANOVA. Error bars: SD. b) Comparison of PHH 
and HDF-derived HLCs from all three donors and ii) with Liv4FA omitted from the results *p>0.05 unpaired 
T test. c) and d) CYP activity as detected using LC-MS-MS method analysing the turnover of probe 
substrates and quantification of metabolites for c) 6β-OH-testosterone (CYP3A) and d) Dextrorphan 
(CYP2D6). * denotes p>0.05 one-way ANOVA. Error bars: SD.  
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Authors Species Starting cell 
types Assays used 
Improved 
phenotype? 
(Liu et al., 2011) Human 
Hepatocytes 
Fibroblasts 
Keratinocytes 
BM-MSCs  
Albumin secretion 
CYP3A4 activity 
Yes,  but non-
significant 
(Lee et al., 2012) Mouse 
Mouse ESCs 
Fibroblasts 
Hepatoblasts 
Hepatocytes 
Albumin secretion 
HLC gene expression Yes, but transient 
(Kajiwara et al., 2012) Human PBMCs 
Fibroblasts Albumin/Urea secretion 
No, donor 
dependent 
(Takayama et al., 
2014) Human 
Hepatocytes 
Fibroblasts 
PBMCs 
HUVECs 
Albumin secretion 
CYP3A4 activity 
TAT expression 
Yes, but transient 
 
Table S1: Summary of the previously published investigations of starting cell type for hepatocyte-like cell 
differentiation  
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Table S2: Primer sequences used for pyrosequencing analysis. 
: Sequencing primer; : Forward primer; : Reverse primer; / : Biotinylated primer. 
 
  
 Name Sequence 5’-3’ Modification 
 HNF4ameth-F  TGGGTGATTAGAAGAATTAATAAG   
 
HNF4ameth-Rb  CAACACAACCACCAAAAAC  5’ biotin 
 
HNF4ameth-S  TGATTAGAAGAATTAATAAGATA   
 FOXA2meth-F  TGTGATTGAAAAGTAATTTTGAA   
 
FOXA2meth-Rb  CAAACAACCCCTCTAACAAC  5’ biotin 
 
FOXA2meth-S  GAAAAGTAATTTTGAAATA   
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  Primer Sequence (5’ to 3’) 
ALB  
F CCTGTTGCCAAAGCTCGATG 
R ATCTCCATGGCAGCATTCGC 
A1AT 
F TCCGATAACTGGGGTGACCT 
R AGACGGCATTGTCGATTCACT 
CYP1A2 
F AGCACCTGCCTCTACAGTTGG 
R TGGTGGACTTTTCAGGCCTTT 
CYP3A4 
F TGTGCCTGAGAACACCAGAG 
R GTGGTGGAAATAGTCCCGTG 
CYP3A7 
F AGACGGGCTTCATCCAATGTG 
R ATGGTGCTAACTGGGGGTGG 
CYP2E1 
F ACCCTGAGATCGAAGAGAAGC 
R AAATGGTGTCTCGGGTTGCT 
CYP2D6 
F TTCCCAAGGGGTGTTCCTGG 
R TCACGGCTTTGTCCAAGAGA 
CK18 
F ACATCCGGGCCCAATATGAC 
R GGTGCTCTCCTCAATCTGCT 
GAPDH 
F CTATAAATTGAGCCCGCAGCC 
R GCCCAATACGACCAAATCCGT 
HNF4α 
F GTTGACGATGGGCAATGACAC 
R TCTTTGTCCACCACGCACTG 
AFP 
F GCGGCCTCTTCCAGAAACTA 
R AATAATGTCAGCCGCTCCCT 
SOX17 
F GGATACGCCAGTGACGACCA 
R GACTTGCCCAGCATCTTGCTC 
FOXA2 
F ATTGCTGGTCGTTTGTTGAGG 
R TTCATGCCGTTCATCCCCAG 
GATA4 
F CGACACCCCAATCTCGATATG 
R GTTGCACAGATAGTGACCCGT 
CXCR4 
F GAAACCCTCAGCGTCTCAGT 
R AGTAGTGGGCTAAGGGCACA 
WNT3 
F GAGCCCAGAGATGTGTACTGC 
R CTTCTAATGGAGCCCCACCT 
PDX1 
F CAAAGCTCACGCGTGGAAAG 
R TTTTTCCACTTCATGCGGCG 
ISL1 (Insulin) 
F ACAAGCAGCCGGAGAAGAC 
R TGGATATTAGTTTTGTCATTGGGCT 
SDHA 
F TGGTTGTCTTTGGTCGGG 
R GCGTTTGGTTTAATTGGAGGG 
OCT4 
F AGACCATCTGCCGCTTTGAG 
R GCAAGGGCCGCAGCTT 
SOX2 
F AACCAGCGCATGGACAGTTAC 
R TGGTCCTGCATCATGCTGTAG 
NANOG 
F GGCTCTGTTTTGCTATATCCCCTAA 
R CATTACGATGCAGCAAATACGAGA 
Table S3: Primer sequences used for qRT-PCR analysis. 
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  DONOR 1 DONOR 2 DONOR 3 
Age at surgery 66 63 27 
        
BMI 27.9 31.2 32.1 
        
Sex Male Female Male 
        
Diagnosis Colorectal carcinoma  
with liver metastases 
Colorectal carcinoma  
with liver metastases 
Focal nodular 
hyperplasia 
        
Co-morbidity 
Type II diabetes mellitus 
Hypertension 
Chronic liver disease 
Type II diabetes mellitus 
None 
No. of PHH-derived 
clones 1 5 10 
 
Table S4: Details of the donors from which the cells used for reprogramming were derived, including key 
parameters such as age, co-morbidities and the number of iPSC clones derived from each donor PHH.  
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Supplementary figure legends 
Figure S1: Protocols for the reprogramming of somatic cells. a) PHH and b) HDF reprogramming 
protocols. Schematic diagram of the protocols used to reprogram each cell type.  PHH: Primary human 
hepatocytes; HDFs: Human dermal fibroblasts; b-FGF: basic fibroblast growth factor 
Figure S2:  Reprogramming of PHH to IPSCs. a) The morphological changes during reprogramming and 
the different cell types which are generated during this period. b) Successfully generated iPSC clone with 
correct morphology and growth characteristics before and after manual picking and passaging. 
Magnification: x100, scale bar: 100µm; x40, scale bar: 100µm.  
Figure S3: Generation and characterization of each iPSC line confirmed by morphology and 
immunofluorescence. Morphology of each line is shown next to the immunofluorescence images of 
nuclear pluripotency markers OCT4, SOX2 and Nanog and surface markers Tra-1-60 and SSEA-4. 
Immunofluorescence images: x200 magnification, 50µm scale bar. Light microscopy images: x100 
magnification, 100µm scale bar.  
Figure S4: Functional pluripotency characterization using embryoid body assay confirmed by 
immunofluorescence. Embryoid bodies generated from each iPSC line and stained for markers of the 
three germ layers associated with pluripotency: Endoderm (AFP), Mesoderm (α-SMA) and Ectoderm 
(Tuj1). Immunofluorescence images: x200 magnification, 50µm scale bar. Light microscopy images: x100 
magnification, 100µm scale bar.  
Figure S5: Wnt3 gene expression determined by q-PCR and presented as 2
-ΔΔ
CT relative to hESC 
comparator and normalized with GAPDH. Error bars represent standard deviation between the means of 
each PHH-/HDF-derived iPSC line which were derived from three individual differentiation cultures. Each 
sample tested by qRT-PCR was loaded in duplicate. 
Figure S6: Differentiation of all lines to hepatocyte-like cells and confirmation by immunofluorescence. 
a) A schematic diagram of the protocol used for the differentiation xperiments, including the growth 
factors/small molecules used at each stage of differentiation. b) Immunofluorescence analysis of iPSCs 
during each stage of differentiation: Definitive endoderm (Sox17), Hepatic endoderm (HNF4α) and 
hepatocyte-like cells (albumin). Immunofluorescence images: x200 magnification, 50µm scale bar. Light 
microscopy images: x100 magnification, 100µm scale bar. 
Figure S7: Comparison of gene expression during hepatocyte-like cell differentiation measured by qRT-
PCR. a) Definitive endoderm associated genes at day 5 of differentiation. All genes shown as 2
-ΔΔ
CT 
relative to a hESC-derived control and normalized using GAPDH and Succinate dehydrogenase gene 
expression. Error bars represent standard deviation between the means of each PHH-/HDF-derived iPSC 
line which were derived from three individual differentiation cultures. Each sample tested by qRT-PCR 
was loaded in duplicate. b) Hepatic endoderm associated genes at day 12 of differentiation. N.B. donor 
1 D.E and H.E samples were not generated during the low passage differentiation experiments and 
therefore are not included in this analysis. 
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Figure S8: Combined gene expression of hepatocyte-like cells derived from PHH and HDF-derived lines. 
Gene expression of key hepatic genes obtained by q-PCR analysis and displayed as 2
-ΔΔ
CT relative to PHH 
of the corresponding donor. N.B. CYP3A4 was not detected in donor 1 and 2 HLCs, results shown are 
derived from donor 3 only. Results normalized using GAPDH and Succinate dehydrogenase. Error bars 
represent standard deviation between the means of each PHH-/HDF-derived iPSC line which were 
derived from three individual differentiation cultures. Each sample tested by qRT-PCR was loaded in 
duplicate. 
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